Ascendis Pharma AS
$ 244.48
0.63%
17 Apr - close price
- Market Cap 14,915,467,000 USD
- Current Price $ 244.48
- High / Low $ 245.57 / 241.64
- Stock P/E N/A
- Book Value -3.13
- EPS -4.45
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -8.18 %
- 52 Week High 250.74
- 52 Week Low 150.89
About
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Analyst Target Price
$296.41
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-06 | 2025-08-07 | 2025-05-01 | 2025-02-12 | 2024-11-14 | 2024-09-03 | 2024-05-02 | 2024-02-07 | 2023-11-07 | 2023-09-05 | 2023-04-27 |
| Reported EPS | -0.55 | -1 | -0.64 | -1.58 | -0.64 | -1.72 | -2.11 | -2.3 | -1.54 | -2.88 | -2.16 | -1.98 |
| Estimated EPS | -0.15 | -0.28 | -1.31 | -1.51 | -0.93 | -1.49 | -1.46 | -1.5 | -2.03 | -2.38 | -2.59 | -2.66 |
| Surprise | -0.4 | -0.72 | 0.67 | -0.07 | 0.29 | -0.23 | -0.65 | -0.8 | 0.49 | -0.5 | 0.43 | 0.68 |
| Surprise Percentage | -266.6667% | -257.1429% | 51.145% | -4.6358% | 31.1828% | -15.4362% | -44.5205% | -53.3333% | 24.1379% | -21.0084% | 16.6023% | 25.5639% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.3 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASND
2026-04-16 13:10:05
Ascendis Pharma is transitioning from American Depositary Shares (ADSs) to a direct listing of its ordinary shares on the Nasdaq, with a one-for-one exchange preserving economic interest. This move aims to simplify its capital-market structure, potentially broadening institutional interest and making cross-stock analysis easier for investors. While the conversion could enhance liquidity and governance, investors should also consider execution risks and the company's concentration in rare disease products during this transition.
2026-04-16 10:40:28
Ascendis Pharma (ASND) has issued 32,310 employee warrants on April 14, 2026, as part of its long-term incentive program, with an exercise price of $249.84. These warrants vest over four years and aim to align employee compensation with shareholder value, while 1,611,843 additional warrants remain available for future grants. Despite strong fundamentals and positive analyst ratings, TipRanks' AI Analyst "Spark" rates the stock Neutral, citing balance sheet risks and negative earnings.
2026-04-15 21:40:28
Ascendis Pharma A/S reported that its board of directors granted an aggregate of 32,310 warrants to certain employees on April 14, 2026. Each warrant allows the holder to subscribe for one ordinary share at an exercise price of US $249.84, mirroring the closing price of the company’s American Depositary Shares on the grant date. The warrants will vest 25% after one year, with the remaining 75% vesting monthly over the subsequent 36 months, subject to continued service and potential earlier vesting upon specific exit events.
2026-04-12 19:10:03
Ascendis Pharma A/S (NASDAQ:ASND) announced plans to list its ordinary shares directly on The Nasdaq Global Select Market, effective April 20, with all ADSs converting to ordinary shares. The company also reported positive Week 52 data from its Phase 2 COACH trial for achondroplasia and that its TransCon CNP therapy, Yuviwel, received orphan drug exclusivity and is now commercially available in the U.S.
2026-04-12 11:39:28
Ascendis Pharma recently announced positive Phase 2 COACH trial data for its TransCon CNP and TransCon hGH combination, showing improved growth and other metrics in children with achondroplasia. Concurrently, the company secured U.S. orphan drug exclusivity for YUVIWEL until 2033 and has begun its commercial launch, bolstering its rare-disease presence. These developments strengthen Ascendis Pharma's investment narrative, with analysts projecting significant revenue and earnings growth, leading to a fair value estimate showcasing a potential upside.
2026-04-09 12:40:28
Wedbush has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US) and maintained a target price of $273. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance.
